Stryker Reports Strong Q4 & Full-Year 2025 Results, Provides Optimistic 2026 Outlook
Summary
Stryker Corporation announced robust fourth quarter and full-year 2025 operating results, featuring double-digit sales and adjusted EPS growth, alongside an optimistic outlook for 2026.
Key Events
-
Strong Q4 2025 Performance
Reported net sales increased 11.4% to $7.2 billion, with organic net sales up 11.0%. Adjusted EPS grew 11.5% to $4.47.
-
Solid Full-Year 2025 Growth
Full-year net sales reached $25.1 billion, an 11.2% increase, and adjusted EPS rose 11.8% to $13.63.
-
Operating Margin Expansion
The company achieved a 100 basis point increase in adjusted operating income margin for both the fourth quarter (30.2%) and full year (26.3%).
-
Positive 2026 Outlook
Stryker anticipates 2026 organic net sales growth between 8.0% and 9.5% and adjusted diluted EPS in the range of $14.90 to $15.10.
Analysis
Stryker's latest earnings report signals strong operational momentum, exceeding $25 billion in annual revenue with consistent double-digit growth in both sales and adjusted earnings per share. The expansion of adjusted operating margins for the second consecutive year underscores effective cost management and operational efficiency. The positive 2026 outlook, projecting continued high-end MedTech growth, provides investors with clear forward guidance and reinforces confidence in the company's sustained performance. This robust financial health positions Stryker favorably within the competitive medical technology sector.
At the time of this filing, SYK was trading at $360.00 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $135.5B. The 52-week trading range was $329.16 to $404.87. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.